308388
Trends in type of insurance coverage for US children, 2003-2012
Methods: We compared the 2003 and 2011-2012 National Surveys of Children's Health, representing 102,353 and 94,500 children, aged 0-17, respectively. Bivariate and multivariable analyses identified changes between 2003 and 2011-2012, by sociodemographic characteristics and health-related factors, including presence of special health care needs (SHCN).
Results: US children with public insurance increased from 27.7% to 37.1%, while there were declines in the proportion with private insurance (63.7% to 56.9%), and those uninsured (8.8% to 5.6%). Public coverage was more commonly reported for children in poor health (58% in 2003, 69% in 2011-2012), or having a SHCN (34% in 2003, 44% in 2011-2012). Public coverage increased for all children, but particularly for Hispanic children. Private coverage declined among children living in poor and near-poor families (≤200% FPL) while public coverage increased for those in households with incomes between >200 - ≤400% FPL. Comparing 2011-2012 to 2003, adjusted relative risks for type of insurance were 1.23 (public), .95 (private), and .60 (uninsured).
Conclusions: Understanding changes in pediatric insurance coverage, particularly for the most vulnerable children, is needed to anticipate future demands on service providers, payers, and families as the Affordable Care Act is fully implemented.
Learning Areas:
EpidemiologyProvision of health care to the public
Public health or related public policy
Public health or related research
Learning Objectives:
Assess the reasons for the shift from private to public insurance for US children.
Discuss the implications of the shift.
Keyword(s): Health Insurance, Child Health
Qualified on the content I am responsible for because: I have published a number of manuscripts on health insurance for children, and have been director of these national surveys.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.